Mutual Enhancement of AcSDKP and G-CSF Activity on the Recovery of CFU-GM in DOX-Treated Mice
| . | Control . | DOX . | DOX AcSDKP . | DOX G-SCF 100 . | DOX AcSDKP G-CSF 100 . | DOX G-CSF 300 . | DOX AcSDKP G-CSF 300 . | DOX G-CSF 500 . | DOX AcSDKP G-CSF 500 . |
|---|---|---|---|---|---|---|---|---|---|
| Mean no. of CFU-GM/leg | 21,614 | 17,140 | 23,951 | 22,966 | 27,250 | 22,934 | 34,400 | 23,267 | 33,363 |
| Standard deviation | 3,823 | 2,140 | 4,751 | 6,287 | 7,349 | 5,972 | 10,744 | 4,627 | 6,970 |
| DOX toxicity | .0001 | ||||||||
| Effect of G-CSF alone | .01 | .01 | .01 | ||||||
| Effect of AcSDKP alone | .0001 | ||||||||
| Potentialization of AcSDKP by G-CSF | NS | .0001 | .0001 | ||||||
| Potentialization of G-CSF by AcSDKP | NS | .002 | .002 | ||||||
| Effect of increasing doses of G-CSF | NS |
| . | Control . | DOX . | DOX AcSDKP . | DOX G-SCF 100 . | DOX AcSDKP G-CSF 100 . | DOX G-CSF 300 . | DOX AcSDKP G-CSF 300 . | DOX G-CSF 500 . | DOX AcSDKP G-CSF 500 . |
|---|---|---|---|---|---|---|---|---|---|
| Mean no. of CFU-GM/leg | 21,614 | 17,140 | 23,951 | 22,966 | 27,250 | 22,934 | 34,400 | 23,267 | 33,363 |
| Standard deviation | 3,823 | 2,140 | 4,751 | 6,287 | 7,349 | 5,972 | 10,744 | 4,627 | 6,970 |
| DOX toxicity | .0001 | ||||||||
| Effect of G-CSF alone | .01 | .01 | .01 | ||||||
| Effect of AcSDKP alone | .0001 | ||||||||
| Potentialization of AcSDKP by G-CSF | NS | .0001 | .0001 | ||||||
| Potentialization of G-CSF by AcSDKP | NS | .002 | .002 | ||||||
| Effect of increasing doses of G-CSF | NS |
AcSDKP (SC injections, 7.2 μg/mouse) was administered 48 hours before DOX. G-CSF was injected IP (100, 300, and 500 ng/injection/mouse, respectively, 4, 5, and 5 experiments, altogether 6 experiments) once a day from day 3 to day 6 after DOX. CFU-GM were monitored at day 7. Student's t-test was performed for statistical analysis.
Abbreviation: NS, not significant.